Holen Sie sich die Stockscreener-App
16.21
2.99%
-0.50
Handel nachbörslich:
16.23
0.02
+0.12%
Schlusskurs vom Vortag:
$16.71
Offen:
$16.91
24-Stunden-Volumen:
17,637
Relative Volume:
0.52
Marktkapitalisierung:
$5.64B
Einnahmen:
$417.75M
Nettoeinkommen (Verlust:
$32.27M
KGV:
166.26
EPS:
0.0975
Netto-Cashflow:
-
1W Leistung:
-3.74%
1M Leistung:
-8.88%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$16.14
$16.98
1-Wochen-Bereich:
$16.14
$17.17
52-Wochen-Spanne:
$13.61
$30.36
Telix Pharmaceuticals Ltd Adr Stock (TLX) Company Profile
Firmenname
Telix Pharmaceuticals Ltd Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie TLX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TLX
Telix Pharmaceuticals Ltd Adr
|
16.21 | 5.64B | 417.75M | 32.27M | 0 | 0.0975 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Telix Pharmaceuticals Ltd Adr Stock (TLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-15 | Eingeleitet | UBS | Buy |
Telix Pharmaceuticals Ltd Adr Aktie (TLX) Neueste Nachrichten
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate - GlobeNewswire Inc.
Former ARTMS Tech Chief Joins Telix to Lead Next-Gen Radiopharmaceutical Innovation - Stock Titan
Major Board Addition: Ex-GSK and Sanofi Leader Joins Telix Pharmaceuticals - Stock Titan
FDA Green Lights Revolutionary Prostate Cancer Detection Tool: What Makes Gozellix a Game-Changer - StockTitan
Telix Pharmaceuticals Limited (ASX:TLX) Receives FDA Approval for Gozellix® - The Capital Club
Paladin Energy Ltd (ASX:PDN) Suspends Operations at Langer Heinrich Mine - The Capital Club
Major Breakthrough: First PSMA-PET Imaging Agent Approved in Brazil's $330M Market - StockTitan
Telix's Game-Changing Isotope Technology Revolutionizes Cancer Treatment Production - StockTitan
Can Telix's Cancer Therapies Transform Urology Treatment? Top Oncologists Weigh In - StockTitan
Could This New Kidney Cancer Imaging Tool Transform Diagnosis? FDA Fast-Tracks Review - StockTitan
Could This New Prostate Cancer Treatment Change Patient Outcomes? Miami Trial Now Recruiting - StockTitan
Telix Pharmaceuticals Ltd (TLPPF) (FY 2024) Earnings Call Highlights: Record Revenue Growth and ... By GuruFocus - Investing.com Canada
Can Telix's Triple Product Launch in 2025 Justify Its Bold $1.2B Revenue Target? - StockTitan
Clinical Trial Success: Telix's Revolutionary Prostate Cancer Treatment Shows Promising Results - StockTitan
Major Breakthrough: Revolutionary Prostate Cancer Detection Tool Gets UK Green Light - StockTitan
Telix Pharmaceuticals acquires ImaginAb assets and technology - Investing.com
Inside Telix's Strategic $45M ImaginAb Acquisition: Next-Gen Cancer Treatment Pipeline Secured - Stock Titan
Telix Pharmaceuticals Acquires RLS USA in Major $230M Radiopharmacy Network Deal - Stock Titan
ImaginAb Sells Therapeutic Pipeline to Telix Pharmaceuticals, Focuses on CD8 ImmunoPET Development - Stock Titan
Telix Pharmaceuticals Hits Record $517M Revenue, Up 55% as Cancer Imaging Portfolio Expands - Stock Titan
Telix Pharmaceuticals Acquires ImaginAb's Cancer Drug Pipeline in $45M Strategic Deal - StockTitan
ASX December health sector winners… and a 91pc drop for a trial-flopped stock - Stockhead
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
Clayton Utz M&A partner Niro Ananda set to resign; KWM eyed - The Australian Financial Review
Health Check: ASX sleep company emerges from slumber with a revenue and earnings upgrade - Stockhead
UBS bullish on Telix stock—Illuccix growth & therapeutic expansion fuel upside - Investing.com
Key Investors Say Bet on These Stocks at Sohn Australia Conference - BNN Bloomberg
TLXTelix Pharmaceuticals Ltd ADR Latest Stock News & Market Updates - Stock Titan
Telix Pharmaceuticals Debuts on Nasdaq Global Select Market Under TLX Symbol - Stock Titan
Liverpool Partners, Adamantem seek new owner for Plena Healthcare - The Australian Financial Review
Telix spins off radiopharma unit to form Rhine Pharma | Pharmaceutical | The Pharmaletter - The Pharma Letter
Guess which top 100 ASX stock is venturing off to the Nasdaq - The Motley Fool Australia
Telix Files Form 20-F Registration Statement for Nasdaq ADS - Yahoo Finance
Up 66% in FY24, will Telix Pharmaceuticals shares continue? - The Motley Fool Australia
TLX ASX: Telix pulls $300m Nasdaq IPO as investors demand deep discount - The Australian Financial Review
Radiopharma-focused Telix heats up IPO summer market with $200M offering - Fierce Biotech
Telix Pharmaceuticals to Acquire IsoTherapeutics Group - Contract Pharma
Pharmaceutical Industry Mergers & Acquisitions Roundup - Contract Pharma
Australia's Telix Pharmaceuticals jumps on potential US listing - Reuters.com
Check Up: These 4 ASX healthcare stocks come with Strong Buy recommendations - Stockhead
Queen's University Leads Irish Trial of New Prostate Cancer Treatment - Imaging Technology News
Morningstar | Empowering Investor Success - Morningstar
Finanzdaten der Telix Pharmaceuticals Ltd Adr-Aktie (TLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.15%
4.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):